Navigation Links
Pharmaceutical companies provide EPA 100 drugs to help predict toxicity
Date:5/13/2010

WASHINGTON - The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process. EPA researchers will quickly screen the drugs and then compare those results with the clinical trial results. Assessment of the similarities and differences in the results will improve EPA's ability to screen chemicals for toxicity.

"For the first time, we'll have both ToxCast screening data and results from toxicology studies and human clinical trials," said Dr. Paul Anastas, EPA's assistant administrator of the Office of Research and Development. "This is an important step in accessing the treasure trove of data that the pharmaceutical industry has in ways that helps protect human health and the environment."

Because of the high cost and the long process of conducting chemical testing, only a small fraction of the thousands of available chemicals have been assessed for potential human health risk. EPA is using its ToxCast screening tool to help efficiently understand how chemicals may impact processes in the human body that could lead to adverse health effects. Currently, ToxCast includes 500 automated chemical screening tests that have assessed more than 300 environmental chemicals.

The clinical trial data will help EPA select the ToxCast screening tests and biological profiles that are the most predictive. The tests and profiles will be used as indicators of potential toxicity for future chemical screening. The ToxCast screening results will be available online for scientists and the interested public to use.

This collaboration was fostered by the International Life Sciences Health and Environmental Science Institute, a non-profit organization of international scientists representing academia, industry, regulatory agencies, and government institutions that come together to reach consensus on complex scientific questions. The organization adopted the inclusion of failed drug candidates into ToxCast as their emerging issue of 2009.


'/>"/>

Contact: Latisha Petteway
petteway.latisha@epa.gov
202-564-3191
U.S. Environmental Protection Agency
Source:Eurekalert

Related medicine news :

1. HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings
2. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
3. Impact Systems Successfully Completes EMC Documentum Migration for Global Pharmaceutical Client
4. Sponsoring by the pharmaceutical industry can bias the results of drug studies
5. Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
6. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results
7. Astellas Responds to OSI Pharmaceuticals Rejection
8. Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
9. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
11. Anthera Pharmaceuticals Completes Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: